# Undecimal Bio

> Uses synthetic biology and AI to discover extrahepatic siRNA-delivery conjugates.

## Why it is interesting

Extrahepatic delivery remains one of RNA medicine’s central bottlenecks; Undecimal is combining large functional screens with computational analysis to search for tissue-targeting conjugates.

## Profile

- **Latest funding:** Seed — $18M (October 13, 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** $18M
- **Stage:** seed
- **Status:** private
- **Industries:** biotech-life-sciences, healthtech, ai-ml
- **Coverage:** full
- **Last updated:** 2026-10-13
- **Latest funding investors:** 4BIO Capital, IQ Capital, Verve Ventures, Harel Tech, Entrée Capital, Kerna Ventures, Saras Capital

## Funding history

- Seed · $18M · October 13, 2026
  Source: https://www.businesswire.com/news/home/20261013517369/en/Undecimal-Bio-launches-with-%2418-million-oversubscribed-Seed-financing-to-address-liver-trap-in-siRNA-therapeutic-delivery

## Investors in our directory

- https://venturecapitaltracker.com/fund/4bio-capital
- https://venturecapitaltracker.com/fund/iq-capital

## Related articles

- https://venturecapitaltracker.com/undecimal-bio-18m-seed-sirna-delivery

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** October 13, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/undecimal-bio